Ensemble Therapeutics has secured its fourth macrocyclic drug discovery collaboration by partnering with Boehringer Ingelheim to discover macrocyclic drug candidates against several undisclosed targets in a deal potentially worth up to US$186 M. Boehringer Ingelheim will have exclusive right to develop and commercialise compounds resulting from the collaboration, which will exploit Ensemble’s DNA-Programmed Chemistry™ (DPC) drug discovery platform, including its Ensemblin™ collection of approximately 5 million macrocycles. Ensemble’s other collaborators include Bristol-Myers Squibb, Pfizer and Roche’s Genentech.